Overview
Portfolio
More
RA Capital Management
Boston, United States
RA Capital invests across multiple stages in healthcare, life‑science, and planetary‑health companies, leveraging an evidence‑based approach powered by its internal TechAtlas research platform. The firm backs innovative...
Portfolio
33+
Employees
250+
Founded
N/A
AUM
≈ $12.6B
Investment focus
Stages
Seed → Series C+
Industries
Artificial IntelligenceBiotechnologyClean TechnologyDigital Health
Geographic scope
Global
Fund details
Funds
RA Capital Planetary Health Fund LP
Vintage 2023 • $116.6M
RA Capital Nexus III Fund LP
Vintage 2022 • $881.0M
RA Capital Nexus II Fund LP
Vintage 2021 • $438.8M
RA Capital Nexus Fund LP
Vintage 2019 • $259.1M
RA Capital Healthcare Fund LP
Vintage 2012 • $10.8B
Check sizes
Max: $75.0M
Sources
RA Capital Management
RA Capital invests across multiple stages in healthcare, life‑science, and planetary‑health companies, leveraging an evidence‑based approach powered by its internal TechAtlas research platform. The firm backs innovative drug, medical‑device, diagnostic, and clean‑technology ventures from seed formation through IPO and follow‑on financing, aiming to create value from inception to commercialization. It seeks opportunities that address significant unmet medical or environmental needs with scalable, data‑driven solutions.
Portfolio
33+
Employees
250+
Founded
N/A
AUM
≈ $12.6B
Funds
RA Capital Planetary Health Fund LP · Vintage 2023 • $116.6M
RA Capital Nexus III Fund LP · Vintage 2022 • $881.0M
RA Capital Nexus II Fund LP · Vintage 2021 • $438.8M
RA Capital Nexus Fund LP · Vintage 2019 • $259.1M
RA Capital Healthcare Fund LP · Vintage 2012 • $10.8B
Check Sizes
Max: $75.0M
Stages
Seed → Series C+
Industries
Artificial IntelligenceBiotechnologyClean TechnologyDigital HealthEnergy
Geographic scope
Global
Sources
Showing 24 of 33 matched portfolio companies
Ansa Biotechnologies utilizes proprietary enzymatic technology to synthesize complex DNA sequences up to 5 kb in length without the need for assembly, enabling the direct synthesis of challenging constructs such as GC-rich sequences and CRISPR arrays. This technology addresses the limitations of traditional DNA synthesis methods, allowing researchers to obtain reliable and rapid access to the complex sequences necessary for advanced scientific projects.
Funding: $83.4M
Rough estimate of the amount of funding raised
Funding: $83.4M
Rough estimate of the amount of funding raised
Astria provides AI tools that automate healthcare back office operations, allowing practices to focus on patient care. The platform integrates with existing EHR systems and ensures compliance with HIPAA regulations, streamlining administrative tasks and improving operational efficiency.
Funding: $125.0M
Rough estimate of the amount of funding raised
Funding: $125.0M
Rough estimate of the amount of funding raised
Boundless Bio is a precision oncology company developing ecDNA-directed therapies (ecDTx) to target oncogene amplified cancers, which affect over 5 million patients annually and currently lack effective treatment options. By leveraging their proprietary Spyglass platform, Boundless Bio identifies and exploits the vulnerabilities associated with extrachromosomal DNA, a key mechanism driving tumor growth and resistance to existing therapies.
Funding: $100.0M
Rough estimate of the amount of funding raised
Funding: $100.0M
Rough estimate of the amount of funding raised
Capacity Bio develops small molecules, peptides, and nanoparticles that enhance the identification and clearance of dysfunctional mitochondria through the activation of mitophagy pathways. This approach addresses the accumulation of suboptimal mitochondria in cells, which contributes to increased reactive oxygen species and cell death during aging and disease.
Funding: $35.0M
Rough estimate of the amount of funding raised
Funding: $35.0M
Rough estimate of the amount of funding raised
Capstan Therapeutics develops targeted lipid nanoparticles (tLNPs) that deliver mRNA and gene editing tools to specific cell types in vivo, enabling precise reprogramming of cells for therapeutic purposes. This technology addresses the need for effective treatments across various diseases, including oncology and genetic disorders, by facilitating safe and repeatable dosing with tailored payloads.
Funding: $340.0M
Rough estimate of the amount of funding raised
Funding: $340.0M
Rough estimate of the amount of funding raised
Cedilla Therapeutics develops targeted small molecules that inhibit specific cancer pathways, aiming to improve treatment efficacy for various malignancies. The company focuses on addressing the limitations of current therapies by providing more precise and effective options for patients with cancer and other diseases.
Funding: $25.0M
Rough estimate of the amount of funding raised
Funding: $25.0M
Rough estimate of the amount of funding raised
CervoMed is developing neflamapimod, a selective small molecule inhibitor of p38 alpha kinase, to reverse synaptic dysfunction in early-stage neurodegenerative diseases such as Alzheimer's and dementia with Lewy bodies. This approach targets the underlying mechanisms of cognitive decline, aiming to improve memory and cognitive function before significant nerve cell damage occurs.
Funding: $149.4M
Rough estimate of the amount of funding raised
Funding: $149.4M
Rough estimate of the amount of funding raised
Claris Biotherapeutics is developing a recombinant human deleted hepatocyte growth factor (dHGF) topical formulation to enhance corneal healing and reduce scarring from various corneal injuries and diseases. This targeted therapy addresses the needs of over 12 million individuals affected by sight-threatening corneal conditions, improving visual outcomes and accelerating recovery.
Funding: $72.6M
Rough estimate of the amount of funding raised
Funding: $72.6M
Rough estimate of the amount of funding raised
Commons Clinic offers bundled surgical care programs for orthopedic, spine, and pain management, utilizing minimally invasive techniques and transparent pricing to enhance patient decision-making. By providing guaranteed rates and comprehensive support from diagnosis through recovery, the clinic addresses the high costs and complexity of specialty surgical care in the ambulatory market.
Funding: $62.3M
Rough estimate of the amount of funding raised
Funding: $62.3M
Rough estimate of the amount of funding raised
Elektrofi utilizes its hyper concentration microparticle technology, Hypercon™, to enable subcutaneous self-administration of biologic therapies, specifically targeting monoclonal antibodies and therapeutic proteins. This approach eliminates the need for intravenous delivery, allowing patients to receive their medications conveniently at home, thereby enhancing treatment adherence and patient autonomy.
Funding: $158.8M
Rough estimate of the amount of funding raised
Funding: $158.8M
Rough estimate of the amount of funding raised
Empatica develops FDA-cleared wearable devices and a health monitoring platform that continuously collects clinical-quality health data and digital biomarkers from everyday life. This technology enables researchers and clinicians to monitor conditions such as epilepsy and movement disorders, enhancing data collection for clinical trials and real-world health insights.
Funding: $25.9M
Rough estimate of the amount of funding raised
Funding: $25.9M
Rough estimate of the amount of funding raised
Everest Medicines is a biopharmaceutical company focused on the discovery and development of novel pharmaceutical therapies and vaccines to meet critical unmet medical needs in Greater China and the Asia Pacific region. Their pipeline includes treatments for conditions such as IgA nephropathy and primary membranous nephropathy, aiming to improve patient outcomes through targeted therapeutic interventions.
100+
5K+Approximate amount of employees
Funding: $310.0M
Rough estimate of the amount of funding raised
Funding: $310.0M
Rough estimate of the amount of funding raised
Evommune develops novel therapeutics targeting the root causes of chronic inflammatory diseases, utilizing specific antagonists like MRGPRX2 to halt disease progression and alleviate symptoms. The company aims to improve patient outcomes by advancing a clinical-stage pipeline that addresses the debilitating effects of chronic inflammation.
Funding: $115.0M
Rough estimate of the amount of funding raised
Funding: $115.0M
Rough estimate of the amount of funding raised
ExcepGen develops a platform that modifies cellular responses to DNA and mRNA, enhancing the efficacy of nucleic acid therapeutics. This approach mitigates undesirable cellular pathways, improving the delivery and effectiveness of gene therapies and vaccines for rare diseases.
Funding: $4.2M
Rough estimate of the amount of funding raised
Funding: $4.2M
Rough estimate of the amount of funding raised
Gameto is a biotechnology company utilizing cell engineering to develop therapeutics for women's reproductive health, focusing on improving in vitro fertilization (IVF) and egg freezing processes. The company addresses significant gaps in fertility treatments and aims to enhance patient outcomes through its innovative platform.
Funding: $75.6M
Rough estimate of the amount of funding raised
Funding: $75.6M
Rough estimate of the amount of funding raised
IDRx is developing IDRX-42, an oral KIT tyrosine kinase inhibitor targeting specific mutations in gastrointestinal stromal tumors (GIST) to enhance treatment efficacy. The company addresses the significant unmet medical need for effective therapies in GIST, where current standards of care have remained unchanged for nearly two decades.
Funding: $242.0M
Rough estimate of the amount of funding raised
Funding: $242.0M
Rough estimate of the amount of funding raised
Innoventric provides the Unica™ heterotopic cross‑caval system, a transcatheter implant that treats severe tricuspid regurgitation by creating a controlled flow pathway between the superior and inferior vena cava and the right atrium, bypassing the native valve. Its anatomy‑agnostic design, low‑profile 26 Fr delivery system, and ability to be implanted under conscious sedation without TEE or general anesthesia enable clinicians to treat high‑risk patients who are ineligible for existing transcatheter therapies.
Funding: $28.5M
Rough estimate of the amount of funding raised
Funding: $28.5M
Rough estimate of the amount of funding raised
Invivyd develops monoclonal antibody candidates for the prevention or treatment of serious viral diseases, starting with COVID-19. The company utilizes a proprietary integrated technology platform to create potent antibodies that resist virus evolution better than the human immune system. Their pipeline focuses on generating these vaccine-alternative antibodies for high-need indications including influenza.
Funding: $336.0M
Rough estimate of the amount of funding raised
Funding: $336.0M
Rough estimate of the amount of funding raised
LianBio is focused on developing and expediting the availability of novel therapeutics for patients in China, specifically targeting unmet medical needs in various disease areas. The company is currently winding down operations and pursuing the sale of its remaining pipeline assets.
Funding: $310.0M
Rough estimate of the amount of funding raised
Funding: $310.0M
Rough estimate of the amount of funding raised
New Equilibrium Biosciences utilizes artificial intelligence to analyze biophysical data, enabling structure-based design in drug development. This platform identifies potential molecular candidates more efficiently, addressing the challenge of time-consuming and costly traditional drug discovery methods.
<3
1K+Approximate amount of employees
Funding: $10.0M
Rough estimate of the amount of funding raised
Funding: $10.0M
Rough estimate of the amount of funding raised
Nodexus provides a microfluidic-based cell sorting system that enables gentle and contamination-free isolation of live single cells for applications in gene editing and drug development. By utilizing low-pressure sorting techniques, the technology maximizes cell viability while allowing researchers to efficiently process diverse cell types, including organoids and spheroids, within a user-friendly interface.
25+
1K+Approximate amount of employees
Funding: $30.0M
Rough estimate of the amount of funding raised
Funding: $30.0M
Rough estimate of the amount of funding raised
Outpace Bio utilizes AI-powered protein design to engineer novel biological functions for cell therapies. The company develops platform technologies like OUTSPACER™, OUTSMART™, and OUTLAST™ to enhance the potency, persistence, and safety of these treatments against solid tumors. This approach programs engineered cells to make optimal decisions within the tumor microenvironment to achieve durable clinical responses.
Funding: $199.0M
Rough estimate of the amount of funding raised
Funding: $199.0M
Rough estimate of the amount of funding raised
Pluton Biosciences utilizes its Micromining Innovation Engine to rapidly discover and clone novel microbes for applications in biopesticides, crop protection, and bioremediation. This platform addresses the need for sustainable solutions in agriculture and environmental management by enabling the production of all-natural bioproducts that enhance human health and combat climate change.
Funding: $25.4M
Rough estimate of the amount of funding raised
Funding: $25.4M
Rough estimate of the amount of funding raised
Rivus Pharmaceuticals develops Controlled Metabolic Accelerators (CMAs), oral small molecules that utilize mitochondrial uncoupling to enhance fat oxidation and improve cellular metabolism. Their lead candidate, HU6, targets obesity and related cardiometabolic diseases by promoting fat-specific weight loss while preserving muscle mass and improving key metabolic parameters.
Funding: $224.0M
Rough estimate of the amount of funding raised
Funding: $224.0M
Rough estimate of the amount of funding raised